Skip to content
Wednesday, August 26, 2026
1 WOMEN'S HEALTHWOMEN'S & REPRODUCTIVE HEALTH

Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab

Women's Health Trial Tracker organizes records from ClinicalTrials.gov API v2 into a static table for transparent comparison. It preserves official source links and dates, marks missing enrichment, and adds deterministic grouping, change, recency, trend, or significance fields only where the documented inputs support them, without recommendations or unsupported claims.

Records
5,000
Last changed
Update schedule
55 1 * * * UTC
Coverage
05/26/2000–08/25/2026
Method
Methodology
Title
Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab
Record Date
07/23/2024
Vuga Group
INTERVENTIONAL
Change Status
unchanged
Recency Days
764.85
Public Significance Score
0